Compare ARCO & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCO | NNNN |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | Uruguay | Germany |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2011 | N/A |
| Metric | ARCO | NNNN |
|---|---|---|
| Price | $8.78 | $26.00 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.60 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 66.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.44 | N/A |
| Revenue Next Year | $9.77 | N/A |
| P/E Ratio | ★ $7.26 | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.51 | $5.91 |
| 52 Week High | $8.98 | $55.65 |
| Indicator | ARCO | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 60.02 | 49.37 |
| Support Level | $7.08 | $20.19 |
| Resistance Level | $8.97 | $31.92 |
| Average True Range (ATR) | 0.28 | 2.94 |
| MACD | 0.00 | 0.45 |
| Stochastic Oscillator | 79.29 | 52.24 |
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Their menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.